ACR Convergence 2020

November 5-9, 2020. All Virtual.

View by Number View by Title View Sessions

View by Date

Jump to: View All • a b c d e f g h i j k [l] m n o p q r s t u v w x y z

Abstract Number: 0602

Labor Impact of SARS-COV-2 Pandemic in Argentine Rheumatologists
Abstract Number: 1409

Lack of Conventional Acinar Cells in the Salivary Gland Following Anti PD-L1 and anti-PD-1 Immune Checkpoint Inhibitor Therapy
Abstract Number: 1254

Lack of Efficacy of Early Treatment with Hydroxychloroquine in a Group of Hispanics with Primary Sjögren’s Syndrome
Abstract Number: 1406

LAG-3+ T Cells Are Diminished in Active Psoriatic Arthritis Patients and Their Restoration in Vitro Is Mediated by TNF Inhibitors
Abstract Number: 2033

Large-scale Examination of Longitudinal Skin Gene Expression and Its Associations with Skin Thickness in Systemic Sclerosis
Abstract Number: 0019

Lasting COVID-19 Impacts on US Rheumatology Practices
Abstract Number: 0937

Late Cardiovascular Outcomes in Children with Kawasaki Disease: A Population-based Cohort Study
Abstract Number: 0858

Leflunomide: A Safe and Effective Alternative in Systemic Lupus Erythematosus
Abstract Number: 1915

Leptin Plays a Critical Role in Modulating Dermal Adipose Tissue, Inflammation and Skin Fibrosis
Abstract Number: 1585

Lessons Learned Through Rapid Quality Improvement for Telehealth Implementation in an Academic Rheumatology Practice During the COVID-19 Pandemic
Abstract Number: 1509

Leukocyte Telomere Length and Childhood Onset of Systemic Lupus Erythematosus in the Black Women’s Experiences Living with Lupus (BeWELL) Study
Abstract Number: 1899

Life Expectancy a Swiss Cohort of Patients with Ankylosing Spondylitis: A 35-Year Follow-up Study
Abstract Number: 1198

Lifestyle and Clinical Risk Factors for Incident Rheumatoid Arthritis-Associated Interstitial Lung Disease Among Patients with Rheumatoid Arthritis
Abstract Number: 0037

Lipoprotein-associated Phospholipase A2: A New Biomarker for Lymphoma Development in Sjögren’s Syndrome
Abstract Number: 0700

Lipoxin A4 Induces Lipid Class Switching and Inflammation Resolution at the Genomic Level in Human Osteoarthritis
Abstract Number: 0703

Liraglutide as a Potential Intra-Articular Treatment for Cartilage Regeneration in Osteoarthritis: In Vitro and In Vivo Studies Supporting a Pro-Chondrogenic Effect
Abstract Number: 0254

LLDAS (Low Lupus Disease Activity State) and Remission Prevent Damage Accrual in Systemic Lupus Erythematosus (SLE) Patients in a Primarily Mestizo Cohort
Abstract Number: 1485

LNA043, a Novel Cartilage Regenerative Treatment for Osteoarthritis: Results from a First-In-Human Trial in Patients with Knee Osteoarthritis
Abstract Number: 0705

lncRNA H19 and Micro RNA 675-3p Are Altered by Visfatin During Osteogenesis
Abstract Number: 0298

Local Genetic Ancestry Associations with Clinical Features of Systemic Lupus Erythematosus
Abstract Number: 2051

Localized versus Systemic Granulomatosis with Polyangiitis: Data from the French Vasculitis Study Group Database
Abstract Number: 0749

Locating Cellular Subsets in Rheumatoid Arthritis Synovium Using CO-Detection by IndEXing (CODEX)
Abstract Number: 0052

Loneliness and Social Isolation Are Important Social Determinants Among Patients from Minority Communities with Rheumatic Diseases
Abstract Number: 1914

Long Non-coding RNA HOTAIR Induces GLI2 Expression Through Notch Signalling in Systemic Sclerosis Dermal Fibroblasts
Abstract Number: L08

Long Term Cardiovascular Safety of Febuxostat and Allopurinol in Patients with Chronic Gout: The Febuxostat versus Allopurinol Streamlined Trial (on Behalf of the FAST Investigators)
Abstract Number: 0720

Long Term Efficacy and Safety of Triamcinolone Hexacetonide versus Triamcinolone Acetonide Intraarticular Injection for Juvenile Idiopathic Arthritis
Abstract Number: 1094

Long Term Open Label Extension of Study of Tofacitinib in Refractory Dermatomyositis
Abstract Number: 0810

Long Term Remission Rates from a Biologic Clinic: 12 Year Real World Data
Abstract Number: 1845

Long-Term Clinical Outcomes of Patients with Lupus Nephritis Treated with an Intensified B-Cell Depletion Protocol: A Matched Case-Control Study
Abstract Number: 1479

Long-Term Effectiveness of Canakinumab in Autoinflammatory Diseases – Interim Analysis of the CAPS Subgroup from the RELIANCE Registry
Abstract Number: 1632

Long-Term Efficacy and Safety of Canakinumab in Patients with Autoinflammatory Periodic Fever Syndromes – First Interim Analysis of the FMF-TRAPS-HIDS/MKD Subgroup of the RELIANCE Registry
Abstract Number: 1486

Long-term Efficacy and Safety of Intra-articular Sprifermin in Patients with Knee Osteoarthritis: Results from the 5-Year Forward Study
Abstract Number: 1626

Long-Term Follow-Up of Renal Transplantation Due to Lupus Nephritis. Single Universitary Center Experience
Abstract Number: 1688

Long-term Hearing Loss, Anxiety and Neurodevelopmental Outcomes Following Kawasaki Disease: A Population-based Cohort Study
Abstract Number: 0811

Long-term Opioid Use in Patients with Rheumatoid Arthritis Treated with Sarilumab
Abstract Number: 1668

Long-Term Outcomes in Children Born to Anti-Ro and/or Anti-La Positive Mothers
Abstract Number: 0907

Long-term Outcomes with Filgotinib, an Oral Selective Janus Kinase 1 Inhibitor: 100-week Data from an Open-label Extension (OLE) Study in Patients with Active Psoriatic Arthritis (PsA)
Abstract Number: 0212

Long-Term Safety and Effectiveness of Upadacitinib or Adalimumab in Patients with Rheumatoid Arthritis: Results at 72 Weeks
Abstract Number: 0210

Long-term Safety and Efficacy of Sarilumab over 5 Years in Patients with Rheumatoid Arthritis Refractory to Tumor Necrosis Factor Inhibitors
Abstract Number: 0240

Long-term Safety and Efficacy of Sarilumab over 5 Years in Patients with Rheumatoid Arthritis with 1 or >1 Prior Tumor Necrosis Factor Inhibitor Failures
Abstract Number: 1630

Long-term Safety of Tildrakizumab in Patients with Moderate to Severe Plaque Psoriasis: Incidence of Confirmed Major Adverse Cardiovascular Events Through 3 Years (148 Weeks) from Two Phase 3 Trials
Abstract Number: 1155

Long-term Safety Profile of Anakinra in Patients with Systemic Juvenile Idiopathic Arthritis
Abstract Number: 0892

Long-Term Safety Profile of Ixekizumab Treatment in Patients with Axial Spondyloarthritis
Abstract Number: 1392

Long-Term Tolerability of Aminaphtone in Raynaud’s Phenomenon Secondary to Systemic Sclerosis
Abstract Number: 1003

Long-term Weight Changes and Risk of Rheumatoid Arthritis Among Women in a Prospective Cohort: A Marginal Structural Model Approach
Abstract Number: 0953

Long-term Xanthine Oxidase Inhibitor Treat to Target Urate Lowering Therapy Coordinately Re-wires the Mononuclear Leukocyte Mitochondrial and Inflammatory Proteome in Gout
Abstract Number: 1507

Longitudinal Analysis of ANA Assay Performance in SLE from the SLICC Inception Cohort
Abstract Number: 1805

Longitudinal Analysis of IFN Status and Disease Characteristics in SLE
Abstract Number: 0307

Longitudinal Analysis of the Patient Pathways to Diagnosis of Psoriatic Arthritis
Abstract Number: 1451

Longitudinal Assessment of Anti-beta 2 Glycoprotein in SLE
Abstract Number: 1812

Longitudinal Blood DNA Methylation in a Multi-ethnic Cohort of SLE Patients
Abstract Number: 1750

Longitudinal Change in the Central Nervous System Pain Response After Treatment with Certolizumab or Placebo. a Post-hoc Analysis from the Pre-CEPRA Trial
Abstract Number: 0713

Longitudinal Effectiveness of Abatacept in JIA: Results from an Ongoing JIA Registry
Abstract Number: 1992

Longitudinal Evaluation of Axonal Dysfunction, Neuronal Markers and Serum Cytokines in Childhood-onset Systemic Lupus Erythematosus
Abstract Number: 1299

Longitudinal Patterns of Anxiety Symptomology Among Patients with Systemic Lupus Erythematosus (SLE) Remain Stable over Time and Do Not Associate with SLE Disease Activity
Abstract Number: 1715

Longitudinal Patterns of Remission in Real-World Early Rheumatoid Arthritis Patients: Results from the Canadian Early Arthritis Cohort (CATCH)
Abstract Number: 1260

Longitudinal Relationships Between Depression, Anxiety and Cognition in Lupus
Abstract Number: 0302

Longitudinal Study of Acute SLE Flare Reveals Dynamic Changes in Multiple Immune Cell Subsets
Abstract Number: 1114

Longitudinally Assessed Structural Abnormalities on MRI and Relative Contributions to Risk of Incident Radiographic Knee Osteoarthritis over 10 Years of Follow-up
Abstract Number: 1670

Low Copy Number of Long C4 Genes Is a Genetic Risk Factor for Childhood Onset SLE (cSLE) but Is Associated with Higher Age of Disease Onset
Abstract Number: 1277

Low Cost Composite Markers to Differentiate Infection from Disease Activity in a Febrile Patient with Systemic Lupus Erythematosus
Abstract Number: 1777

Low Dose Aspirin to Prevent Pre-eclampsia in SLE Pregnancies – Counselling Helps to Realize Our Full Potential
Abstract Number: 0559

Low Frequency of ANA/DFS70 Pattern Positive Result in a Large Cohort of Autoimmune/autoinflammatory Diseases Compared with First Degree Relatives and Healthy Controls Evaluated in a Single Hospital from Colombia
Abstract Number: 1924

Low Immunogenicity in Patients with Giant Cell Arteritis Treated with Tocilizumab: 3-Year Results from the Randomized Controlled Portion and the Open-Label Follow-Up of a Phase 3 Trial
Abstract Number: 0435

Low Incidence of Coronavirus Disease 2019 (COVID-19) Infection in Patients on Biologic Infusion Therapies at a Community Rheumatology Practice
Abstract Number: 0938

Low Preconceptional Complement Level Is Related with an Adverse Obstetric Outcome in a Multicentric Cohort of Pregnancy in Patients with APS and aPL Positivity
Abstract Number: PP02

Low- and Hi-Tech Tools for Enhancing Patient-Hospital Care Team Communication in the Context of Rare Disease
Abstract Number: 0699

Lumbar Spine Stenosis Treatment : Is Surgery Better Than Medical Treatment in Afro-Descendant Populations ?
Abstract Number: 1297

Lupus Antibodies in Relation to Malignancy
Abstract Number: 1680

Lupus Anticoagulant as a Predictor of Adverse Outcomes in Children with Venous Thromboembolism
Abstract Number: 1298

Lupus Damage Free-Survival by Age at Diagnosis: A Retrospective Incident Lupus Cohort
Abstract Number: 1829

Lupus Disease Activity After Cessation of Anifrolumab Treatment During the Phase 2b MUSE Trial Follow-up Period
Abstract Number: 0247

Lupus Low Disease Activity State Achievement Is Important for Reducing Adverse Outcomes in Pregnant Patients with Systemic Lupus Erythematosus
Abstract Number: 1770

Lupus Low Disease Activity State Protects Against Pre-Term Birth
Abstract Number: 0250

Lupus Nephritis and Renal Outcomes in African-Americans: The Accelerating Medicines Partnership Cohort Experience
Abstract Number: 0273

Lupus Nephritis Is Associated with a Reduced Prevalence of Fibromyalgia
Abstract Number: 0462

Lupus-like Autoimmunity and Increased Interferon Response in Patients with STAT3-deficient Hyper-IgE Syndrome
Abstract Number: 0792

LY294002 Improves the Collagen-induced Arthritis by Inducing Neutrophil Apoptosis
Abstract Number: 1557

Lymphatics as a Biomarker of Joint Physiology: Near-Infrared Imaging of Indocyanine Green Identifies Novel Routes of Lymphatic Drainage from Metacarpophalangeal Joints in Healthy Human Hands
Abstract Number: 0460

Lymphocyte Clonal Expansion Distinguishes Different Forms of Uveitis
Abstract Number: 0184

Lymphomas Complicating Rheumatoid Arthritis: Results of a French Multi-Centre Case-Control Study

Jump to: View All • a b c d e f g h i j k [l] m n o p q r s t u v w x y z

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].